Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice Long

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
European Journal of Immunology|January 13, 2022
Guidelines for standardizing T-cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetesJennie H M Yang, Kirsten A Ward-Hartstonge, Daniel J Perry, et al.
Immunotherapy Advances|January 24, 2022
A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetesAshish K Marwaha, Samuel Chow, Anne M Pesenacker, et al.
Diabetes|June 23, 2012
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell functionS Alice Long, Mary Rieck, Srinath Sanda, et al.
JCI Insight|November 1, 2019
A composite immune signature parallels disease progression across T1D subjectsCate Speake, Samuel O Skinner, Dror Berel, et al.
The Lancet. Diabetes & Endocrinology|July 2, 2021
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen E Gitelman, Brian N Bundy, Ele Ferrannini, et al.
Medrxiv : the Preprint Server for Health Sciences|May 3, 2023
Type 1 Diabetes Prevention: a systematic review of studies testing disease-modifying therapies and features linked to treatment responseJamie L Felton, Kurt J Griffin, Richard A Oram, et al.
American Journal of Respiratory Cell and Molecular Biology|July 1, 2024
PD-L1 and PD-1 Are Associated with Clinical Outcomes and Alveolar Immune Cell Activation in Acute Respiratory Distress SyndromeEric D Morrell, Sarah E Holton, Alice Wiedeman, et al.
Communications Medicine|October 4, 2023
Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic reviewJamie L Felton, Kurt J Griffin, Richard A Oram, et al.
Cell Reports. Medicine|November 2, 2023
Inhibition of polyamine biosynthesis preserves β cell function in type 1 diabetesEmily K Sims, Abhishek Kulkarni, Audrey Hull, et al.
The New England Journal of Medicine|June 11, 2019
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 DiabetesKevan C Herold, Brian N Bundy, S Alice Long, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
European Journal of Immunology|January 13, 2022
Guidelines for standardizing T-cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetesJennie H M Yang, Kirsten A Ward-Hartstonge, Daniel J Perry, et al.
Immunotherapy Advances|January 24, 2022
A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetesAshish K Marwaha, Samuel Chow, Anne M Pesenacker, et al.
Diabetes|June 23, 2012
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell functionS Alice Long, Mary Rieck, Srinath Sanda, et al.
JCI Insight|November 1, 2019
A composite immune signature parallels disease progression across T1D subjectsCate Speake, Samuel O Skinner, Dror Berel, et al.
The Lancet. Diabetes & Endocrinology|July 2, 2021
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen E Gitelman, Brian N Bundy, Ele Ferrannini, et al.
Medrxiv : the Preprint Server for Health Sciences|May 3, 2023
Type 1 Diabetes Prevention: a systematic review of studies testing disease-modifying therapies and features linked to treatment responseJamie L Felton, Kurt J Griffin, Richard A Oram, et al.
American Journal of Respiratory Cell and Molecular Biology|July 1, 2024
PD-L1 and PD-1 Are Associated with Clinical Outcomes and Alveolar Immune Cell Activation in Acute Respiratory Distress SyndromeEric D Morrell, Sarah E Holton, Alice Wiedeman, et al.
Communications Medicine|October 4, 2023
Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic reviewJamie L Felton, Kurt J Griffin, Richard A Oram, et al.
Cell Reports. Medicine|November 2, 2023
Inhibition of polyamine biosynthesis preserves β cell function in type 1 diabetesEmily K Sims, Abhishek Kulkarni, Audrey Hull, et al.
The New England Journal of Medicine|June 11, 2019
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 DiabetesKevan C Herold, Brian N Bundy, S Alice Long, et al.
Pageof 9